RPL30

Across TCGA pan-cancer cohorts, RPL30 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPL30 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPL30 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL30 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, GBM, and HNSC are the cancer types where RPL30 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.619	0.911	<.001	48	view →
GBM	DFS	Median	All	0.249	0.482	<.001	17	view →
HNSC	OS	Median	III,IV	0.934	0.773	.023	14	view →
PDAC	OS	Median	IV	0.491	0.836	.024	11	view →
LSCC	OS	Tertile	II,III,IV	0.948	0.590	.012	11	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPL30–CCRCC (DFS)

Open the CCRCC breakdown →